(HealthDay)—Robot-assisted minimally invasive surgery for kidney cancer is associated with considerable benefits, which outweigh health care and surgical costs, according to a study published in the February issue of Health ...
Feb 6, 2015
0
19
Patients with operable kidney cancers were more likely to have a partial nephrectomy—the recommended treatment for localized tumors—when treated in hospitals that were early adopters of robotic surgery, according to a ...
Dec 11, 2014
0
0
(HealthDay)—Deep venous thrombosis (DVT) and pulmonary embolism (PE) are uncommon after urological surgery, according to a study published in the September issue of The Journal of Urology.
Sep 3, 2014
0
0
Surgery is often the first step in treating kidney cancer, and new data from the University of Rochester Medical Center, which contradicts earlier research, questions whether removal of only the tumor (partial nephrectomy) ...
Jul 24, 2013
0
0
(HealthDay)—Over the last 30 years, the incidence of nephrectomy at post-chemotherapy (PC) retroperitoneal lymph node dissection (RPLND) has steadily declined, according to research published in the March issue of The Journal ...
Apr 3, 2013
0
0
Urologists at Henry Ford Hospital have developed a new technique that could make minimally invasive robotic partial nephrectomy procedures the norm, rather than the exception for kidney cancer patients. The technique spares ...
Dec 13, 2012
0
0
In the largest study of its kind, living donors who had a kidney removed through a single port in the navel report higher satisfaction in several key categories, compared to donors who underwent traditional multiple-port ...
Sep 12, 2012
0
0
Researchers at the University of California, San Diego School of Medicine have identified a link between patients who undergo total nephrectomy - complete kidney removal - and erectile dysfunction. Results from the multi-center ...
Jul 30, 2012
0
0
Kidney cancer patients who had only their tumor removed had better survival than patients who had their entire kidney removed, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.
Apr 17, 2012
0
0
(HealthDay) -- The potent, selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, tivozanib, demonstrates antitumor activity and is well tolerated in patients with advanced/metastatic renal cell carcinoma ...
Apr 10, 2012
0
0
